PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsIoflupane i-123
Ioflupane i 123
Celsunax, DaTscan, Ioflupane I (ioflupane i 123) is a small molecule pharmaceutical. Ioflupane i 123 was first approved as Datscan on 2011-01-14. It has been approved in Europe to treat dementia, movement disorders, and radionuclide imaging.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
diagnosisD003933
mental disordersD001523
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
datscanNew Drug Application2024-01-10
ioflupane i 123ANDA2022-12-16
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
55 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Parkinsonian disordersD020734G20.C1113
SyndromeD013577112
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Parkinson diseaseD010300EFO_0002508G201146
Essential tremorD020329EFO_0003108G25.0112
TremorD014202R25.1112
Shy-drager syndromeD012791EFO_100105011
Multiple system atrophyD01957811
AtrophyD00128411
Progressive supranuclear palsyD013494EFO_0002512G23.111
Vascular dementiaD015140F0111
Alzheimer diseaseD000544EFO_0000249F0311
Lewy body diseaseD020961EFO_0006792G31.8311
Show 1 more
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients11
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Movement disordersD009069EFO_0004280G2511
Wounds and injuriesD014947T14.811
Traumatic brain injuriesD000070642S0611
Brain injuriesD001930S06.911
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameIoflupane i 123
INNioflupane (123i)
Description
Ioflupane I(123) is an azabicycloalkane that is ecgonine methyl ester in which the N-methyl group is replaced by 3-fluoropropyl and the 3beta-hydroxy group is replaced by 4-((123)I)iodophenyl. Used for the imaging of dopamine transporters in the brain of adult patients with potential Parkinsonian Syndromes. It has a role as a radioactive imaging agent and a radiopharmaceutical. It is an azabicycloalkane, an organofluorine compound and a methyl ester. It is functionally related to an ecgonine.
Classification
Small molecule
Drug classiodine-containing contrast media
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
COC(=O)[C@H]1[C@@H](c2ccc([123I])cc2)C[C@@H]2CC[C@H]1N2CCCF
Identifiers
PDB
CAS-ID155798-07-5
RxCUI
ChEMBL IDCHEMBL3989517
ChEBI ID
PubChem CID3086674
DrugBankDB08824
UNII ID3MM99T8R5Q (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,649 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
477 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use